Foghorn posts Q3 net loss of $19.1M; first patient dosed in Phase 1 for FHD-909

Foghorn Therapeutics Inc.

2024-Q3 EPS reported -$1.28 revenue$19,746,000

Revenue $7.8M vs $17.5M year ago; net loss $19.1M vs $14.3M year ago.
Cash $267.4M as of Sept 30, 2024; expects cash runway into 2027.
First patient dosed with FHD-909 (SMARCA2 inhibitor) in Phase 1 for SMARCA4 mutant NSCLC.
Topline Phase 1 data for FHD-286 + decitabine in AML expected by year-end 2024.
Appointed Anna Rivkin as Chief Business Officer in September 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.